

Diagnostics Accelerator Investigators' Meeting

October 7-9, 2020

Online

Wednesday, October 7, 2020

SESSION I	Ocular and Emerging Protein Biomarkers of ADRD, Biomarkers for FTD	CO-CHAIRS: Robert Dean, MD, PhD, Robert A. Dean Consulting Tetsuyuki Maruyama, PhD, KPY Consulting
10:00-10:05	Welcome & Introductory Notes	Howard Fillit, MD, Alzheimer's Drug Discovery Foundation
10:05-10:10	Session Overview	CO-CHAIRS: Robert Dean, MD, PhD, Robert A. Dean Consulting Tetsuyuki Maruyama, PhD, KPY Consulting
10:10-10:25	Delivering Novel Neuro-retinal Biomarkers for the Early Diagnosis of Alzheimer's Disease	Thomas MacGillivray, PhD, University of Edinburgh
10:25-10:40	Findings from the RetiSpec Hyperspectral Imaging System in Individuals with Preclinical and Early Alzheimer's Disease: A Preliminary Report	Eliav Shaked, MSc, RetiSpec Catherine Bornbaum, PhD, MBA, RetiSpec
10:40-10:55	Fully Automated Plasma Assays as Screening Tests for Alzheimer-related Amyloid Beta Pathology	Henrik Zetterberg, MD, PhD, University of Gothenburg
10:55-11:10	Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer's Disease	Stephen Zicha, PhD, Foundation for the National Institutes of Health Wesley Horton, MS, Foundation for the National Institutes of Health
11:10-11:25	Tau and p-tau as Alzheimer Biomarkers - Assays, Methodological Aspects and Clinical Performance	Kaj Blennow, MD, PhD, University of Gothenburg
11:25-11:40	TABLOOD: A Biomarker Panel for Direct Assessment in Blood of Alzheimer's Disease Pathophysiological Hallmarks	Douglas Galasko, MD, University of California San Diego
11:40-12:00	QUESTIONS and DISCUSSION	Robert Dean, MD, PhD, Robert A. Dean Consulting
12:00-12:05	BREAK	
12:05-12:20	Studies on the Plasma Contact System in Alzheimer's Disease	Sidney Strickland, PhD, The Rockefeller University Erin Norris, PhD, The Rockefeller University
12:20-12:35	Novel Platform for On-Chip Detection of Neuronal Extracellular Vesicle-Bound Peripheral Biomarkers for Alzheimer's Disease and Other Dementias	Amber Murray, PhD, Biological Dynamics
12:35-12:50	Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation before Clinical Onset of Dementia	Blaine Roberts, PhD, Emory University
12:50-13:05	Protein Misfolding Cyclic Amplification (PMCA) Clinical Test for Detection of Aggregates of Misfolded Aβ-Synuclein	Russell Lebovitz, MD, PhD, Amprion Inc.
13:05-13:20	Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)	Laura Mitic, PhD, Bluefield Project to Cure FTD
13:20-13:35	Using Large Data Approaches to Diagnose and Drug Dementia	Judith Steen, PhD, Boston Children's Hospital
13:35-13:55	QUESTIONS and DISCUSSION	Tetsuyuki Maruyama, PhD, KPY Consulting
13:55-14:00	CLOSING REMARKS	Robert Dean, MD, PhD, Robert A. Dean Consulting Tetsuyuki Maruyama, PhD, KPY Consulting

Thursday, October 8, 2020

SESSION II	Part 1: Molecular Biomarkers of ADRD	CHAIR: James Gallarda, PhD, Dx Consultancy
	Part 2: Digital Biomarkers of ADRD	CHAIR: Lampros Kourtis, PhD, Circadic.io
10:00-10:05	Welcome & Introductory Notes	James Gallarda, PhD, Dx Consultancy
10:05-10:20	Liquid Biopsy to Detect Cell Death in Alzheimer's Disease	Yuval Dor, PhD, Hebrew University
10:20-10:35	Validation of a Rapid Non-invasive Diagnostic Test to Predict MCI and early Alzheimer's Disease	Hueseyin Firat, MD, PhD, Amoneta Diagnostics S.A.S.
10:35-10:50	Blood-Based miRNA Diagnostics of Alzheimer's Disease	Bruno Steinkraus, PhD, Hummingbird Diagnostics GmbH
10:50-11:05	Mitochondrial Epigenetics, a Tool for An Early AD Diagnosis	Marta Barrachina, PhD, ADmit Therapeutics S.L.
11:05-11:20	Plasma Cell-Free RNA as Alzheimer's Disease Non-invasive Biomarker	Laura Ibanez, PhD, Washington University
11:20-11:35	Association between Plasma microRNA and other AD Markers in Cognitively Normal Study Participants	Kira Sheinerman, PhD, MBA, Diamir Biosciences
11:35-11:50	Aptamer Diagnosis of Alzheimer's Risk Factor in Blood	Gregory Penner, PhD, NeoNeuro
11:50-12:10	QUESTIONS and DISCUSSION	James Gallarda, PhD, Dx Consultancy
12:10-12:15	BREAK	#colspan#
12:15-12:20	Introduction to the session on Digital Biomarkers	Lampros Kourtis, PhD, Circadic.io
12:20-12:35	Novel Virtual Reality Method to Distinguish Apathy from Depression in the Context of Dementia	Ramit Ravona-Springer, MD, Sheba Medical Center
12:35-12:50	Digitally-enhanced Personalized Medicine: Accurate Selection of Subjective Cognitive Decline and Measuring Progression of Mild Cognitive Impairment	Carolina Minguillon, PhD, BarcelonaBeta
12:50-13:05	Smartphone-based Learning and Memory Assessment (Lila™): Beta Application Development	Chris Edgar, PhD, Cogstate Ltd
13:05-13:20	Alzheimer's Disease Digital Biomarker Discovery: Framingham Cognitive Aging and Dementia Study	Rhoda Au, PhD, Boston University
13:20-13:35	Detecting Cognitive Impairment and Measuring Cognitive Change: Responding to Modern Challenges	Jennifer Rae Myers, PhD, Neurotrack
13:35-13:55	QUESTIONS and DISCUSSION	Lampros Kourtis, PhD, Circadic.io
13:55-14:00	Closing Remarks	Niranjan Bose, PhD, Gates Ventures

Friday, October 9, 2020

Session III	Digital and Ocular Biomarkers	CO-CHAIRS: Nicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation Eric Siemers, MD, Siemers Integration LLC
17:00-17:05	Welcome & Introductory Notes	Nicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation
17:05-17:20	Machine Learning Technologies for Advancing Digital Biomarkers for Alzheimer's Disease	Guolian Xing, DSc, The Chinese University of Hong Kong
17:20-17:35	Threats to Digital Biomarkers and how Data Sharing Can Help	Larsson Omberg, PhD, Sage Bionetworks
17:35-17:50	A Retinal Imaging Biomarker of Alzheimer's Disease	Peter Van Wijngaarden, MBBS, PhD, FRANZCO, Center for Eye Research Australia
17:50-18:05	QUESTIONS & DISCUSSION	Nicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation Eric Siemers, MD, Siemers Integration LLC
18:05-18:15	CLOSING REMARKS	Howard Fillit, MD, Alzheimer's Drug Discovery Foundation Niranjan Bose, PhD, Gates Ventures